What's hot!

View all perspectives
What's Hot

New axSpA Criteria: Who gets left out?

Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.  

Watch video →

What Happens when CAR-T Fails Managing Disease Recurrence

Dr. Alfred Kim discusses abstracts OP0076 and OP0333 presented at EULAR 2026.

Watch video →

‘Strong’ Treatment Predictions in Inflammatory Myositis

Dr. Janet Pope, reports on abstracts POS0264 and OP0166, presented at the 2026 EULAR meeting in London.

Watch video →

Imaging in Subclinical Psoriatic Arthritis

Dr. Antoni Chan discusses abstract OP068 presented at EULAR 2026.

Watch video →

Are we failing in the treatment of RA-ILD?

Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.

Watch video →

PsA Potpourri: Probiotics & Head-to-Head Data

Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.

Watch video →

Combination Biologics in PsA: MRI Findings from AFFINITY

Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.  

Watch video →

How Many CAR-Ts Do We Need to Test Drive?

Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.

Watch video →

BMI Outranks Treatment in PsA Outcomes?

Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.

Watch video →

Dietary Interventions in PsA

Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.

Watch video →

Low dose Blinatumomab: Many Relapse with an Unexpected Surprise

Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London. 

Watch video →

Renal Biopsies in SLE

Dr. Andrea Fava reporting from EULAR 2026 in London.

Watch video →

RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk

Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London 

Watch video →

Day 4 Recap: EULAR 2026

Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.

Watch video →

EULAR 2026 Recommendations: Immunization

Dr. Jiha Lee reporting from EULAR 2026 in London.

Watch video →

Making Methotrexate More Effective

Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London

Watch video →

Day 3 Recap: EULAR 2026

Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288

Watch video →
CAR T on purple background

5 years since Patient ID001: Progress on CAR-T Therapy in RMD

Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?

Read more →
      Treating inflammation and obesity in PsA with IXEKIZUMAB AND CONCOMITANT TIRZEPATIDE effective with no new safety signal

      Jiha Lee JihaRheum

      2 months 1 week ago
      Treating inflammation and obesity in PsA with IXEKIZUMAB AND CONCOMITANT TIRZEPATIDE effective with no new safety signals OP069 @RheumNow #EULAR2026 https://t.co/rkhYvZWpHn
      TOGETHER-PsA :ACR50 was already significantly higher with IXE+TZP as early as Week 4 (11.1% vs 3.9%, p=0.029). The metab

      Antoni Chan MD (Prof) synovialjoints

      2 months 1 week ago
      TOGETHER-PsA :ACR50 was already significantly higher with IXE+TZP as early as Week 4 (11.1% vs 3.9%, p=0.029). The metabolic and anti-inflammatory effects of GLP-1/GIP agonism may act synergistically Abstr#069 @RheumNow #EULAR2026 https://t.co/NBQ6CccuCn
      TOGETHER PsA trial
      IXE+TIRZEPATIDE TZP vs. IXE alone RCT
      Obese or Overweight PsA IR to <3 bioDMARDs

      Primary endpoint

      https://twitter.com/

      2 months 1 week ago
      TOGETHER PsA trial IXE+TIRZEPATIDE TZP vs. IXE alone RCT Obese or Overweight PsA IR to <3 bioDMARDs Primary endpoint ≥10% weight & ACR50 wk 36 31.7% IXE+TZP vs. 0.8% for IXE alone ACR50 IXE+TZP 33.5% & IXE 20.4%, p=0.02) No clear difference by gender/age/BMI/previous DMARDs https://t.co/lFbeb85b9Y
      Cancer risk with JAK inhibitors remains a major focus at #EULAR2026. In #OP086, analysis from 14 international RA regist

      Mrinalini Dey DrMiniDey

      2 months 1 week ago
      Cancer risk with JAK inhibitors remains a major focus at #EULAR2026. In #OP086, analysis from 14 international RA registries and >60000 treatment courses found no statistically significant increase in overall or subtype-specific malignancy risk with JAKi versus TNFi. @RheumNow https://t.co/JeOmTufYwo
      #EULAR2026 Abstr# OP06 9 TOGETHER-PsA: Adding tirzepatide to ixekizumab in #PsA + obesity achieved the primary composite

      Antoni Chan MD (Prof) synovialjoints

      2 months 1 week ago
      #EULAR2026 Abstr# OP06 9 TOGETHER-PsA: Adding tirzepatide to ixekizumab in #PsA + obesity achieved the primary composite (ACR50 + ≥10% weight loss) in 31.7% vs just 0.8% with IXE alone at 36 weeks (p<0.001). The first trial tackling PsA + obesity simultaneously @RheumNow https://t.co/0cDAj1y7OF
      Abst# OP068: 68Ga-RGD PET/CT imaging detected subclinical synovitis in 35% of joints that were clinically silent in #PsA

      Antoni Chan MD (Prof) synovialjoints

      2 months 1 week ago
      Abst# OP068: 68Ga-RGD PET/CT imaging detected subclinical synovitis in 35% of joints that were clinically silent in #PsA. Molecular imaging may reveal the true burden of joint disease before it declares clinically. @RheumNow #EULAR2026 #PsoriaticArthritis
      Small interventional synovial biopsy precision medicine study

      CD117 high pts n=15 = better response to IL17i or IL23i i

      Aurelie Najm AurelieRheumo

      2 months 1 week ago
      Small interventional synovial biopsy precision medicine study CD117 high pts n=15 = better response to IL17i or IL23i inhibition vs. TNFi w/ -DAPSA -13.5, -12.8 vs. -7.5 respectively Higher BL levels of tissue inflammation in Responders vs. NR More robust study design needed https://t.co/7jNff6lUJ6
      #OP085 from Sweden adds more real-world data to the JAKi safety discussion at #EULAR2026. In >26000 RA treatment init

      Mrinalini Dey DrMiniDey

      2 months 1 week ago
      #OP085 from Sweden adds more real-world data to the JAKi safety discussion at #EULAR2026. In >26000 RA treatment initiations, JAKis were associated with higher VTE risk vs TNFi (HR 1.89), with similar findings persisting in 2021-2024 data. @RheumNow https://t.co/YRjPNZ8mmo
      #EULAR2026 OP076 Of 50 patients treated with autologous CAR-T, 12% relapsed; median 13 mths. More frequent in #IIM vs #S

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 months 1 week ago

      #EULAR2026 OP076 Of 50 patients treated with autologous CAR-T, 12% relapsed; median 13 mths. More frequent in #IIM vs #SLE or #SSc. These relapses were significant. Switching to BCMA-CAR or BCMA-TCE restored response. Should BCMA instead of CD19 be targeted initially?@RheumNow https://t.co/lgdsJQm3xY

      Kicking off Clinical Abstracts: Comorbidities in RA session at #EULAR2026 with #OP084

      ANCHOR-RA found 9.1% at-risk RA p

      Mrinalini Dey DrMiniDey

      2 months 1 week ago
      Kicking off Clinical Abstracts: Comorbidities in RA session at #EULAR2026 with #OP084 ANCHOR-RA found 9.1% at-risk RA patients had previous undiagnosed ILD on screening HRCT. Older age, smoking, male sex & ⬆️DAS28 linked to RA-ILD. Important data for earlier detection @RheumNow
      💊 Oral IL-23Ri for #PsA #PsO?

      ICONIC RCT (n=216):
      Yes! Icotrokinra improves pain & disease activity at week 16

      Nelly ZIADE 🍀 Nellziade

      2 months 1 week ago
      💊 Oral IL-23Ri for #PsA #PsO? ICONIC RCT (n=216): Yes! Icotrokinra improves pain & disease activity at week 16 #POS0052 #EULAR2026 @RheumNow https://t.co/PA4O36h02Y
      🛡️ Can secukinumab prevent #PsA?

      SERENA real-world study (n=1,334):
      Yes!
      97% PsA-free at 5yrs

      #POS0051 #EULAR202

      Nelly ZIADE 🍀 Nellziade

      2 months 1 week ago
      🛡️ Can secukinumab prevent #PsA? SERENA real-world study (n=1,334): Yes! 97% PsA-free at 5yrs #POS0051 #EULAR2026 @rheumnow
      💉 Add tirzepatide to biologics in obese #PsA?

      #POS0050: Yes! Propensity score-matched study (n=93):
      better PROs, HA

      Nelly ZIADE 🍀 Nellziade

      2 months 1 week ago
      💉 Add tirzepatide to biologics in obese #PsA? #POS0050: Yes! Propensity score-matched study (n=93): better PROs, HAQ & PASI at 6 months #EULAR2026 @RheumNow @vincevenerito https://t.co/rrhNKZByjc
      🎯 Does Tofacitinib work in axial #PsA?

      #POS0049: 1st RCT (PASTOR, n=26):
      improved MRI & clinical outcomes vs pl

      Nelly ZIADE 🍀 Nellziade

      2 months 1 week ago
      🎯 Does Tofacitinib work in axial #PsA? #POS0049: 1st RCT (PASTOR, n=26): improved MRI & clinical outcomes vs placebo @ wk12 #EULAR2026 @rheumnow
      You CAN identify #ILD in #rheumatic #diseases
      🔜early
      With a brief #questionnaire

      Ask re
      ➡️dry cough
      ➡️dysp

      Janet Pope Janetbirdope

      2 months 1 week ago
      You CAN identify #ILD in #rheumatic #diseases 🔜early With a brief #questionnaire Ask re ➡️dry cough ➡️dyspnea ➡️smoking Not sensitive but high #specificity Is it too late? Maybe chest #auscultation at the #bases would be better? 🤷 #EULAR2026 ABST#POS0433 @RheumNow https://t.co/JA3k1cSHt7

      Podcasts

      • RheumNow EULAR 2026 Rheumatology Round Up
      • EULAR 2026 RA Topic Panel
      • CAR-T Topic Panel EULAR 2026

      Catch up on Conference Podcasts

      ×